



Accepted Abstracts for CROI 2017

Protocol	Title	Authors	Presentation Type
<i>Tuesday, 14 February 2017</i>			
P1104s	Neuropsychological outcomes in a two year African-based pediatric observational study	Boivin MJ, Chernoff M, Laughton B, Bwakura-Dangarembizi M, Kamthunzi P, Barlow-Mosha L, Violari A, Cotton M, Palumbo P, for the IMPAACT P1104s Study Team	Poster
IMPAACT 219C	Biomarkers of cognitive decline in perinatally-infected children with HIV	Bearden DR, Gill A, Williams PL, Kolson DL, Schankel L, Agwu A, Van Dyke RB, Douglas SD, for the IMPAACT 219C study team	Poster
IMPAACT 219C	Plasma Heme-Oxygenase-1 is associated with cognitive decline in children with HIV	Bearden DR, Gill A, Williams PL, Kolson DL, Schankel L, Agwu A, Van Dyke RB, Douglas SD, for the IMPAACT 219C study team	Poster
<i>Wednesday, 15 February 2017</i>			
P1026s	Interaction between etonogestrel-releasing implant and 3 antiretroviral regimens	Kreitchmann R, Stek A, Best B, Capparelli E, Wang J, Shapiro DE, Chakhtoura N, Burchett S, Mirochnick M	Poster
P1072	B and T cell subsets and immunogenicity of rotavirus vaccine in PHIV and PHEU Infants	Weinberg A, Lindsey JC, Bosch R, Persaud D, Sato P, Heckman B, Richardson K, Zadzilka A, Nelson M, Levin MJ	Poster
PHOENIX IMPAACT 2003/A5300	HIV testing uptake among household contacts of MDR-TB index cases in eight countries	Opollo VS, Wu X, Lando R, Swindells S, Gupta A, Hesselning A, Dawson R, Hughes MD, Shah S	Poster
<i>Thursday, 16 February 2017</i>			
P1025, DACS 711, SMARTT	TDF/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts	Rough K, Seage III GR, Williams PL, Hernandez-Diaz S, Huo Y, Chadwick EG, Hoffman RM, Barr E, Shapiro DE, Patel K	Poster
P1026s	Elvitegravir/cobicistat pharmacokinetics in pregnancy and postpartum	Best B, Capparelli E, Stek A, Acosta E, Smith E, Chakhtoura N, Wang J, Hernandez A, Mirochnick M	Poster



Accepted Abstracts for CROI 2017

Protocol	Title	Authors	Presentation Type
<i>Thursday, 16 February 2017 (continued)</i>			
PROMISE 1077BF/FF	Antenatal antiretroviral therapy and adverse birth outcomes: the PROMISE trial	Chi BH, Farhad M, Owor M, Chipato T, Qin M, Dadabhia S, Gnanashanmugam D, Chakhtoura N, Fowler MG, Stringer JS	Poster
PROMISE 1077BF/FF	Risk factors for low birth weight and preterm delivery in the PROMISE trial	Sebikari D, Qin M, Owor M, Stringer J, Farhad M, Chakhtoura N, Chi B, Klingman K, Theron G, Fowler MG	Poster
PROMISE 1077HS	Subsequent pregnancy outcomes in women during follow-up in PROMISE 1077HS	Pilotto JH, Brummel S, Hoffman RM, Britto P, Masheto G, Aurpibul L, Chakhtoura N, Klingman K, Currier JS	Poster
P1080	Sertraline pharmacokinetics in HIV-infected on ARV and uninfected youth	Hanan N, PAUL M, Huo Y, Capparelli E, Kapetanovic S, Ariansen JL, Smith E, Brouwers P, Best B	Poster
P1093	Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to <6 years old	Ruel T, Acosta E, Singh RP, Alvero C, George K, Popson S, Vavro C, Hazra R, Wiznia A	Poster
P1106	Pharmacokinetics of nevirapine prophylaxis in HIV-exposed low birth weight infants	Bekker A, Violari A, Cababasay M, Wang J, Wiesner L, Capparelli E, Cotton M, Nakwa F, Mirochnick M	Poster
P1110	Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study	Clarke DF, Acosta EP, Chain A, Wang J, Cababasay M, Tepler H, Smith E, Hazra R, Mirochnick M, and the IMPAACT P1110 Protocol Team	Poster
P1112	Safety & pharmacokinetics of the monoclonal antibody, VRC01, in HIV-exposed newborns	Cunningham CK, McFarland EJ, Capparelli EV, Muresan P, Perlowski C, Valentine M, Smith E, Mascola JR, Graham BS	Poster